Pancreatitis Clinical Trial
Official title:
Perioperative Intravenous Administration of High Volume Lactated Ringer's Solution and the Risk of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
The purpose of this study is to examine whether giving large amounts of intravenous (IV) fluids will reduce the risk of developing a complication known as post-ERCP pancreatitis (PEP). Pancreatitis is inflammation of the pancreas, and it is the most frequent serious complication of ERCP. Typically, a small amount of IV fluids are given during this procedure (~ 1 liter). We are testing whether using a larger amount of fluids (2 - 3 liters) will reduce the risk of PEP.
This trial is designed as a phase II/III study. The phase II portion of the trial will be
completed to establish safety and efficacy data prior to proceeding with a phase III study.
The phase II trial will enroll 110 patients that are undergoing elective ERCP as outpatients.
Following the phase II portion, if the data suggests that the intervention arm (high volume
group) is safe, the investigators will begin enrolling patients who are undergoing ERCP in a
more urgent setting as inpatients.
We plan on enrolling 1,400 consecutive high risk patients undergoing ERCP. We are assuming a
baseline PEP risk of 9.2%. Fluid administration will be based on Ideal Body Weight (IBW) in
order to standardize the aggressive fluid administration across all body weights and reduce
the potential for adverse cardiopulmonary outcomes.
All participants will be monitored for 90 minutes following their procedure to assess the
development of any adverse symptoms. Analysis by a data safety monitoring board (DSMB) will
take place throughout the study. The DSMB is comprised of a panel of experts independent of
NorthShore University HealthSystem.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03609944 -
SpHincterotomy for Acute Recurrent Pancreatitis
|
N/A | |
| Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
| Completed |
NCT01441492 -
Pancreas Resection With and Without Drains
|
N/A | |
| Recruiting |
NCT02196935 -
Los Angeles Prospective GI Biliary and EUS Series
|
||
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
| Completed |
NCT01545167 -
The North American Pancreatitis Study
|
N/A | |
| Completed |
NCT04168801 -
Early Oral Refeeding in Mild Acute Pancreatitis
|
N/A | |
| Recruiting |
NCT03334708 -
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
|
||
| Completed |
NCT01824186 -
Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy
|
N/A | |
| Terminated |
NCT00428025 -
Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients
|
Phase 4 | |
| Completed |
NCT00639314 -
Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy
|
N/A | |
| Recruiting |
NCT00160836 -
Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter
|
Phase 1 | |
| Completed |
NCT00999232 -
Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube
|
Phase 4 | |
| Completed |
NCT00121901 -
Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?
|
Phase 3 | |
| Terminated |
NCT00419549 -
Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05095831 -
EUS Shear Wave for Solid Pancreatic Lesions.
|
||
| Completed |
NCT03601325 -
Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
|
||
| Not yet recruiting |
NCT06133023 -
WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts
|
N/A | |
| Withdrawn |
NCT02465138 -
A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis
|
Phase 4 | |
| Recruiting |
NCT02971475 -
ESWL Versus ESWL and Endoscopic Treatment
|
N/A |